摘要 免疫排斥抑制抗肿瘤免疫和免疫治疗反应,其机制尚未明晰。在三阴性乳腺癌(TNBC)中,这是一种侵袭性且通常免疫丰富的亚型,免疫冷微环境预测预后不良,因对化疗和免疫检查点抑制剂响应有限。为识别调控TNBC免疫浸润的机制,我们进行了免疫丰富与免疫冷肿瘤的空间转录组分析。结果显示滋养层细胞表面抗原2(TROP2),作为抗癌抗体药物偶联物(ADCs)的关键靶点,通过与闭合蛋白7结合及紧密连接调控,控制TNBC中的屏障介导的免疫排斥。TROP2表达与T细胞浸润呈负相关,并预测TNBC不良预后。功能缺失与重构实验表明,TROP2足以通过依赖CD8 T细胞的机制驱动体内肿瘤进展,而其缺失则扰乱多种紧密连接蛋白的表达与定位,促进T细胞浸润。采用人源化TROP2同系TNBC模型,我们发现通过hRS7(ADC Sacituzumab govitecan(SG)的抗体成分)靶向TROP2,可增强抗PD1反应,改善T细胞可及性及效应功能。相应地,TROP2表达高度相关于人类乳腺癌中对抗PD1治疗缺乏响应。因此,TROP2控制的免疫排斥程序可作为靶点以增强免疫治疗反应。引用格式:B. Wu et al. Trop2 remodeling of the immune microenvironment in triple negative breast cancer abstract. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-12-29.
Building similarity graph...
Analyzing shared references across papers
Loading...
B. Wu
Win Thant
Elena Bitman
Clinical Cancer Research
Massachusetts General Hospital
Massachusetts Eye and Ear Infirmary
Building similarity graph...
Analyzing shared references across papers
Loading...
Wu等人(星期二,)研究了该问题。
www.synapsesocial.com/papers/6996a8e3ecb39a600b3f01d5 — DOI: https://doi.org/10.1158/1557-3265.sabcs25-ps3-12-29
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: